Therapeutic vaccines preferentially stimulate T cells against tumour-specific epitopes that
are created by DNA mutations or oncogenic viruses. In the setting of premalignant disease …

Tumour formation involves the co-evolution of neoplastic cells together with extracellular
matrix, tumour vasculature and immune cells. Successful outgrowth of tumours and eventual …

One in seven men in North America is expected to be diagnosed with prostate cancer (PCa)
during their lifetime (,). While a wide range of treatment options including surgery, radiation …

The clinical outcomes of conventional mono-chemotherapy of cancers are usually far from
satisfactory due to some issues such as tumor heterogeneity and resistance to …

It has recently become clear that the tumour microenvironment, and in particular the immune
system, has a crucial role in modulating tumour progression and response to therapy …

Accumulating evidence indicates that the innate and adaptive immune systems make a
crucial contribution to the antitumour effects of conventional chemotherapy-based and …

Relapse is a major problem in acute myeloid leukemia (AML) and adversely affects survival.
In this phase 2 study, we investigated the effect of vaccination with dendritic cells (DCs) …

Background CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA
(RNActive®) encoding the antigens PSA, PSCA, PSMA, and STEAP1. This phase I/IIa study …

Cancer immunotherapy faces a serious challenge because of low clinical efficacy. Recently,
a number of clinical studies have reported the serendipitous finding of high rates of objective …

Certain chemotherapeutic regimens trigger cancer cell death while inducing dendritic cell
maturation and subsequent immune responses. However, chemotherapy‐induced …